Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA

Affiliation auteurs!!!! Error affiliation !!!!
TitreDaratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
Type de publicationJournal Article
Year of Publication2019
AuteursSonneveld P, Attal M, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj-Merzoug K, Karlin L, Benboubker L, Levin M-D, Minnema M, Westerman M, Delforge M, Zweegman S, Pei L, de Boer C, Vanquickelberghe V, Kampfenkel T, Moreau P
JournalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume19
PaginationE2-E3
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN2152-2650
Mots-clésdaratumumab, Multiple myeloma, transplant
DOI10.1016/j.clml.2019.09.004